One of the prerequisites for the successful treatment of cancer is selective or “targeted” therapy. Particularly important in this respect are recent advances in the conjugation of cytotoxic compounds to tumor-specific targeting molecules (see picture). The current trend is aimed at minimizing the size of the conjugates.
No takes yet. Share an insight, caveat, or question.
Maison et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: